infant acellular pertussis-containing vaccine

Infant acellular pertussis-containing vaccine refers to a category of pediatric combination vaccines designed to provide active immunity against *Bordetella pertussis* (whooping cough), *Corynebacterium diphtheriae* (diphtheria), and *Clostridium tetani* (tetanus). Unlike traditional whole-cell pertussis (wP) vaccines, acellular (aP) formulations utilize purified, inactivated components of the pertussis bacterium, such as pertussis toxoid (PT), filamentous hemagglutinin (FHA), and pertactin (PRN), which are associated with a significantly lower risk of local and systemic adverse reactions. These vaccines are typically administered as a primary series in infancy (e.g., at 2, 4, and 6 months of age) and are often formulated as multi-antigen products that may also include protection against polio (IPV), Hepatitis B, and *Haemophilus influenzae* type b (Hib). In clinical research, such as the M-PRIME trial, these vaccines serve as standard-of-care comparators to evaluate the impact of maternal immunization on infant immune responses and to compare the immunogenicity of different pertussis vaccination schedules.

Other names

acellular pertussis vaccineaP-containing vaccineDTaPpediatric acellular pertussis vaccineDTaP-containing vaccine